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Introduction
Human papillomaviruses (HPVs) are the cause of cervical
intraepithelial neoplasia and invasive carcinomas of the
uterine cervix. The distribution of specific HPV genotypes
varies greatly across populations and HPV surveys have
been performed in different geographical regions to apply
appropriate vaccine strategies. The aim of this study was to
determine the spectrum of HPV genotypes and HPV-16
variants among women with cervical lesions living in
Ecuador.
Methods
A total of 71 cases have been analyzed, including 32
chronic cervicitis, 29 cervical intraepithelial neoplasia
grade 1, and 10 cervical intraepithelial neoplasia grade 2–
3. HPV sequences were detected by broad spectrum con-
sensus-primer-pairs MY09/MY11 and GP5+/GP6+-based
polymerase chain reaction and characterized by nucle-
otide sequence analysis.
Results
Overall, 31 (43.7%) cases were HPV-positive with preva-
lence rates of 37.5 percent, 44.8 percent and 60 percent in
patients with chronic cervicitis, cervical intraepithelial
neoplasia grade 1 and cervical intraepithelial neoplasia
grade 2–3, respectively. Among the positive cases, the
most common genotypes were HPV 16 (64.5%) and HPV
81 (29%) followed by HPV 31, 53, 56, and 58, in
descending order of prevalence. Seventeen (85%) HPV-16
isolates were classified as European and three (15%) as
African 1 variant on the basis of nucleotide signature
present within the MY09/MY11 L1 sequence.
Discussion
The results suggest that 1) HPV 16 has a very high preva-
lence among women with cervical lesions in Ecuador;
therefore, an effective HPV-16 based vaccine should pre-
vent the development of cervical cancer in a large propor-
tion of Ecuadorian women; and 2) HPV type 81, which
has not been included in the most used detection systems
and has not been searched for in the majority of epidemi-
ological studies on HPV survey, is very frequent among
women with cervical lesions in Ecuador and among HIV-
positive women in Brazil and Italia (Cerqueira et al.,
2007; Tornesello et al., 2008) underscoring the need to
target a wide range of HPV types in cervical cancer screen-
ing programs.
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